ReviewInternational urology and nephrology2015
Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy.
Review in International urology and nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- A clinical study on roxadustat for anemia in diabetic nephropathy: a 8-week study.International urology and nephrology · 2024Article
- Association between anemia and the risk and outcomes of diabetic foot in patients with type 2 diabetes mellitus.Experimental and therapeutic medicine · 2023Article
- Prevalence of anemia and its associated factors among patients with type 2 diabetes mellitus in a referral diabetic clinic in the north of Iran.BMC endocrine disorders · 2023Article
- Analysis of clinical predictors of kidney diseases in type 2 diabetes patients based on machine learning.International urology and nephrology · 2023Article
- Editorial: Rising stars in renal endocrinology: 2021.Frontiers in endocrinology · 2023Article
- Anemia is a risk factor for rapid eGFR decline in type 2 diabetes.Frontiers in endocrinology · 2023Article
- Effects of the route of erythropoietin administration on hemoglobin variability and cardiovascular events in hemodialysis patients.Kidney research and clinical practice · 2021Article
- Impact of the relationship between hemoglobin levels and renal interstitial fibrosis on long-term outcomes in type 2 diabetes with biopsy-proven diabetic nephropathy.BMC nephrology · 2021Article
- Novel Iron Parameters in Patients with Type 2 Diabetes Mellitus in Relation to Kidney Function.Journal of clinical medicine · 2021Article
- Treatment of anemia in difficult-to-manage patients with chronic kidney disease.Kidney international supplements · 2021Article
- Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin.Advances in therapy · 2021Review
- Anemia and Its Associated Factors Among Type 2 Diabetes Mellitus Patients Attending Debre Berhan Referral Hospital, North-East Ethiopia: A Cross-Sectional Study.Journal of blood medicine · 2020Article
- Anemia in patients of diabetic kidney disease.Journal of the Chinese Medical Association : JCMA · 2019Review
- Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa.International journal of nephrology and renovascular disease · 2019Article
- Effects of inspiratory muscle training on pulmonary functions and muscle strength in sedentary hemodialysis patients.Journal of physical therapy science · 2018Article
- Article
- Management of anemia in patients with diabetic kidney disease: A consensus statement.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is currently considered a modern global epidemic, and diabetic nephropathy (DN) is the most common cause of chronic kidney disease (CKD). Anemia is one of the most significant complications of CKD, and it is mainly attributed to insufficient erythropoietin (EPO) production. However, anemia develops earlier in the course of CKD among patients with DM, and the severity of anemia tends to be more marked in these patients compared to nondiabetic subjects, regardless of the stage of CKD. In this review, we focus on the "less known" complex interacting mechanisms which are involved in the pathophysiology of anemia associated with DN. Although the major cause of anemia in DN is considered to be an inappropriate response of the plasma EPO concentration to anemia, several other possible mechanisms have been suggested. Glomerular hyperfiltration, proteinuria, renal tubular dysfunction and interstitial fibrosis are among the main culprits. On the other hand, systemic effects such as chronic inflammation, autonomic neuropathy and the renin-angiotensin system are also involved. Finally, several medications are considered to aggravate anemia associated with DN. Since anemia is an important predictor of quality of life and is implicated in the increased burden of cardiovascular morbidity and mortality, further research is required to elucidate its pathogenesis in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.